1 Min Read
June 26 (Reuters) - Dermira Inc
* Dermira - Findings from nonclinical studies evaluating mechanism of action for olumacostat glasaretil in sebum inhibition were published
* Dermira Inc - An additional open-label trial, claritude, is evaluating long-term safety of olumacostat glasaretil.
* Dermira Inc - Topline results from clareos-1 and clareos-2 trials are expected in first half of 2018. Source text for Eikon: Further company coverage: